DASATINIB 302962-49-8

Function of Dasatinib

Dasatinib (DASA tin IB), used for all treatment stages (chronic phase, accelerated phase) Stage, lymphoid cell blast crisis and myeloid blast crisis) adult patients. At the same time, the FDA also approved Dasatinib through normal procedures to treat Philadelphia chromosome-positive acute lymphoblastic leukemia adult patients who are resistant or intolerant to other therapies.

Dasatinib inhibits BCR-ABL kinase and SRC family kinases as well as many other selective oncogenic kinases, including c-KIT, ephrin (EPH) receptor kinase and PDGFβ receptor. Dasatinib is a potent, subnanomolar BCR-ABL kinase inhibitor with a strong activity at a concentration of 0.6 to 0.8 nmol. It can be combined with the inactive and active configurations of the BCR-ABL enzyme.

In vitro studies, dasatinib is active in leukemia cell lines expressing various imatinib-sensitive and drug-resistant diseases. The results of these non-clinical studies indicate that dasatinib can overcome imatinib resistance caused by: BCR-ABL overexpression, BCR-ABL kinase region mutations, kinases including SRC family kinases (LYN, HCK) in Over-expression of other signaling pathways within, as well as multidrug resistance genes. In addition, dasatinib can inhibit SRC family kinases at this nanomolar concentration

In an in vivo experiment conducted using the murine CML model alone, dasatinib prevented the progression of chronic phase CML to the acute phase, while prolonging tumor-bearing mice (derived from patient CML cell lines growing in different locations, including the central Nervous system)

*Products under the patent are only for R&D use